CompanyGraph
Sisram Medical Ltd.
1696 · HKEX · Israel
Price data from its SRAMF listing on OTC, quoted in USD
sisram-medical.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $244.21M, lower than 95% of all stocks globally
- PositionP/E ratio is 6.95×, lower than 95% of its Medical Devices peers (median 31.47×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.82%Above 5Y avg (2.79%)
Annual Rate
HKD 0.13Paid annual
Payout Ratio
39.7%Sustainable
Payback Period
3.5 yr
Next Ex-Dividend
Aug 26, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
1.92BHKD244.21M · vs all stocks (USD)
Trailing P/E
6.95xvs Medical Devices peers
Revenue (TTM)
2.87BHKD365.48M · vs all stocks (USD)
Profit Margin
5.21%vs Medical Devices peers
Beta
0.6670xvs all stocks
52-Week Change
-69.03%vs all stocks
Market Capitalization
1.92BHKD244.21M · vs all stocks (USD)
Enterprise Value
8.20BHKD1.04B · vs all stocks (USD)
Trailing P/E
6.95xvs Medical Devices peers
Forward P/E
3.32xvs Medical Devices peers
Price to Sales (TTM)
2.85xvs Medical Devices peers
Price to Book (MRQ)
0.2766xvs Medical Devices peers
Enterprise to Revenue
2.86xvs Medical Devices peers
Enterprise to EBITDA
27.33xvs Medical Devices peers
Gross Margin
55.33%vs Medical Devices peers
Profit Margin
5.21%vs Medical Devices peers
Operating Margin
9.17%vs Medical Devices peers
Return on Assets (TTM)
2.63%vs Medical Devices peers
Return on Equity (TTM)
5.06%vs Medical Devices peers
Revenue (TTM)
2.87BHKD365.48M · vs all stocks (USD)
Revenue per Share (TTM)
0.7800HKDUpdated Aug 19, 2026Quarterly Revenue Growth
10.80%vs Medical Devices peers
Gross Profit (TTM)
1.69BHKD215.22M · vs all stocks (USD)
EBITDA (TTM)
28.18MHKD3.59M · vs all stocks (USD)
Net Income (TTM)
149.21MHKD19.02M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-11.20%vs Medical Devices peers
Operating Cash Flow (TTM)
73.74MHKD9.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
40.17MHKD5.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1260HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
5.82%vs all stocks
5-Year Average Dividend Yield
2.79%vs all stocks
Payout Ratio
39.68%vs Medical Devices peers
Minority Interest (Equity)
23.83MUSDFY2025 · Dec 31, 2025Revenue
365.35MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
150.20MUSDFY2025 · Dec 31, 2025Gross Profit
215.14MUSDFY2025 · Dec 31, 2025Operating Income
32.55MUSDvs all stocks (USD)
Pre-tax Income
28.55MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.54MUSDFY2025 · Dec 31, 2025Net Income
25.00MUSDFY2025 · Dec 31, 2025EBIT
31.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
49.14MUSDFY2025 · Dec 31, 2025Research & Development
16.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
165.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
961.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0406USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0406USDFY2025 · Dec 31, 2025Basic Shares Outstanding
468.34MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
468.34MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-5.99MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-5.76MUSDFY2025 · Dec 31, 2025Free Cash Flow
-8.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
70.83MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
28.55MUSDFY2025 · Dec 31, 2025Stock-based Compensation
0.00USDFY2025 · Dec 31, 2025Other Non-cash Items
2.28MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.64MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.96MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.58MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.58MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
24.58MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-18.70MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-7.54MUSDFY2025 · Dec 31, 2025Other Financing Charges
2.69MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
1.02MUSDFY2025 · Dec 31, 2025Shares Outstanding
468.34MSharesUpdated Aug 19, 2026Float Shares
133.16MSharesUpdated Aug 19, 2026% Held by Insiders
71.57%vs all stocks
% Held by Institutions
0.47%vs all stocks
Total Cash (MRQ)
573.11MHKD73.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1560HKDUpdated Aug 19, 2026Total Debt (MRQ)
406.08MHKD51.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1027xvs Medical Devices peers
Current Ratio (MRQ)
2.60xvs Medical Devices peers
Book Value per Share (MRQ)
8.04HKDUpdated Aug 19, 2026Total Assets
657.26MUSDvs all stocks (USD)
Total Current Assets
276.29MUSDFY2025 · Dec 31, 2025Total Liabilities
153.57MUSDFY2025 · Dec 31, 2025Total Non-current Assets
380.96MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
47.32MUSDFY2025 · Dec 31, 2025Total Current Liabilities
106.25MUSDFY2025 · Dec 31, 2025Cash
70.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
70.97MUSDFY2025 · Dec 31, 2025Accounts Receivable
92.59MUSDFY2025 · Dec 31, 2025Inventory
93.29MUSDFY2025 · Dec 31, 2025Accounts Payable
22.93MUSDFY2025 · Dec 31, 2025Short-term Debt
16.29MUSDFY2025 · Dec 31, 2025Long-term Debt
35.46MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.33MUSDFY2025 · Dec 31, 2025Retained Earnings
183.22MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
503.68MUSDvs all stocks (USD)
52-Week Low
2.10HKDUpdated Aug 19, 202652-Week High
7.19HKDUpdated Aug 19, 202652-Week Change
-69.03%vs all stocks
Beta
0.6670xvs all stocks
50-Day MA
2.37HKDUpdated Aug 19, 2026200-Day MA
3.43HKDUpdated Aug 19, 2026Avg 10-Day Volume
165.19KSharesUpdated Aug 19, 2026Avg 30-Day Volume
290.35KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.3200HKDUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 6.95×, lower than 95% of its Medical Devices peers (median 31.47×)Notable
P/E ratio: 6.95Industry median: 31.47Industry P5: 13.95Peers compared: 102
Price-to-book is 0.28×, lower than 95% of its Medical Devices peers (median 2.69×)Notable
Price-to-book: 0.28Industry median: 2.69Industry P5: 0.66Peers compared: 102
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 19,022,830.709Operating Cash Flow (USD, TTM): 9,401,375.739
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: 0.05
Financial Health
Altman Z-Score 2.37: grey zoneSignificant
Altman Z-Score: 2.37
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $244.21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 244,210,058.633Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Dongguan Changlian New Materials Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ASGN Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Doximity Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated